Invokana, Invokamet side effects $1.5M class action settlement

Janssen Pharmaceuticals agreed to pay $1.5 million to resolve claims Invokana and Invokamet can have serious side effects that may result in kidney injuries and lower limb amputations.

The settlement benefits Canada residents who were prescribed Invokana, Invokamet and/or Invokamet XR before June 21, 2022, and who experienced a diagnosis of acute kidney injury or acute renal failure before April 25, 2016, a diagnosis of diabetic ketoacidosis before Aug. 31, 2016, or a lower limb amputation before Dec. 6, 2017.

According to several class action lawsuits, Janssen knew its Invokana and Invokamet medications could cause serious side effects but failed to warn consumers. The plaintiffs claim the diabetes medications can increase the risk of lower limb amputations, ketoacidosis, acute renal failure, acute kidney injuries and even death. 

Invokana, Invokamet and Invokamet XR are type-2 diabetes medications from Janssen. Janssen and parent company Johnson & Johnson have been accused of hiding serious side effects associated with Invokana and the other drugs in order to increase their profits.

Janssen and Johnson & Johnson haven’t admitted any wrongdoing but agreed to a $1.5 million settlement to resolve the class action lawsuits.

Under the terms of the settlement, class members can receive a cash payment based on their documented injuries linked with Invokana or Invokamet. 

Payments will be determined by assigning point values to injuries and using those points to calculate a proportional share of the net settlement fund. For example, acute kidney injuries are assigned eight points, while leg amputations above the knee are assigned 32 points. 

There is no exclusion or objection deadline for the settlement.

The settlement was granted final approval in Saskatchewan on Sept. 29, 2022, in Quebec on Nov. 23, 2022, and in Ontario on Sept. 30, 2022.

The deadline to submit a claim in the Invokana side effects settlement is Aug. 14, 2023.

Who’s Eligible

Canadian residents who were prescribed Invokana, Invokamet and/or Invokamet XR before June 21, 2022, and who experienced a diagnosis of acute kidney injury or acute renal failure before April 25, 2016, a diagnosis of diabetic ketoacidosis before Aug. 31, 2016, or a lower limb amputation before Dec. 6, 2017

Potential Award

Varies

Proof of Purchase

Proof of injury and prescriptions.

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

08/14/2023

Case Name

Estate of Raymond Duck v. Janssen Inc., et al., Case No. CV-18-00000570-00CP, in the Ontario Superior Court of Justice

Varnai, et al. v. Janssen Inc., et al., Case No. 500-06-000906-186, in the Superior Court of Quebec for the District of Montreal

Fiddler v. Janssen Inc., et al., Case No. Q.B.G. 2809/2015, in the Court of Queen’s Bench for Saskatchewan for the Judicial Centre of Regina

Final Hearing

09/29/2022

Settlement Website

InvokanaCanadaSettlement.com

Claims Administrator

Trilogy Class Action Services
Invokana® Class Action Settlement
117 Queen Street, P.O. Box 1000,
Niagara-on-the-Lake, Ontario L0S 1J0
claims@trilogyclassactions.ca
877‑400‑1211

Class Counsel

James Boyd
Chloé Faucher-Lafrance
SISKINDS LLP

EF Anthony Merchant, QC
MERCHANT LAW GROUP LLP

Defense Counsel

BLAKE CASSELS & GRAYDON LLP